KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Convertible Debt (2020 - 2026)

Esperion Therapeutics filings provide 6 years of Convertible Debt readings, the most recent being $97.3 million for Q4 2025.

  • On a quarterly basis, Convertible Debt rose 0.53% to $97.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $97.3 million, a 0.53% increase, with the full-year FY2025 number at $97.3 million, up 0.53% from a year prior.
  • Convertible Debt hit $97.3 million in Q4 2025 for Esperion Therapeutics, roughly flat from $97.1 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $272.5 million in Q3 2021 to a low of $96.7 million in Q4 2024.
  • Median Convertible Debt over the past 5 years was $260.1 million (2022), compared with a mean of $221.4 million.
  • Biggest five-year swings in Convertible Debt: skyrocketed 44.0% in 2021 and later crashed 63.06% in 2025.
  • Esperion Therapeutics' Convertible Debt stood at $258.3 million in 2021, then increased by 0.63% to $259.9 million in 2022, then increased by 0.65% to $261.6 million in 2023, then plummeted by 63.02% to $96.7 million in 2024, then grew by 0.53% to $97.3 million in 2025.
  • The last three reported values for Convertible Debt were $97.3 million (Q4 2025), $97.1 million (Q3 2025), and $97.0 million (Q2 2025) per Business Quant data.